Issued Patents All Time
Showing 25 most recent of 39 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 11666320 | Fixation members, assemblies, and related systems and methods | Samantha JOHNSON, Joseph Algeri, David B. Spenciner, Dennis E. Connelly, Reagan A. Theis | 2023-06-06 |
| 9765340 | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2017-09-19 |
| 9745585 | RNAi-mediated inhibition of histamine receptor H1-related conditions | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2017-08-29 |
| 9533053 | High concentration olopatadine ophthalmic composition | Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh | 2017-01-03 |
| 9453220 | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders | John M. Yanni, John E. Chatterton, Steven T. Miller | 2016-09-27 |
| 9447419 | RNAi-mediated inhibition of tumor necrosis factor α-related conditions | John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Steven T. Miller | 2016-09-20 |
| 9371529 | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2016-06-21 |
| 9206428 | RNAi-mediated inhibition of histamine receptor H1-related conditions | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2015-12-08 |
| 8865671 | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2014-10-21 |
| 8791154 | High concentration olopatadine ophthalmic composition | Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh | 2014-07-29 |
| 8673873 | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2014-03-18 |
| 8618278 | RNAi-mediated inhibition of histamine receptor H1-related conditions | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2013-12-31 |
| 8541389 | RNAi-mediated inhibition of tumor necrosis factor α-related conditions | John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Steven T. Miller | 2013-09-24 |
| 8222227 | RNAi-mediated inhibition of histamine receptor H1-related conditions | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2012-07-17 |
| 8138205 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | Steven P. Govek, Clay Beauregard, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau +2 more | 2012-03-20 |
| 8048863 | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2011-11-01 |
| 8017592 | RNAi-mediated inhibition of histamine receptor H1-related conditions | John M. Yanni, Jon E. Chatterton, Steven T. Miller | 2011-09-13 |
| 7923471 | Method of treating dry eye disorders and uveitis | Peter G. Klimko, Mark R. Hellberg | 2011-04-12 |
| 7879905 | 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | Peter G. Klimko, Mark R. Hellberg, David P. Bingaman | 2011-02-01 |
| 7732421 | RNAI-mediated inhibition of tumor necrosis factor α-related conditions | John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Steven T. Miller | 2010-06-08 |
| 7026296 | Methods of treating dry eye disorders | — | 2006-04-11 |
| 6872382 | Use of selective PDE IV inhibitors to treat dry eye disorders | John M. Yanni | 2005-03-29 |
| 6825232 | Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders | — | 2004-11-30 |
| 6696453 | Use of NF-&kgr;B inhibitors to treat dry eye disorders | John M. Yanni | 2004-02-24 |
| 6645978 | Lipoxin A4 and its analogs for the treatment of dry eye | Gustav Graff, Mark R. Hellberg, Peter G. Klimko, John M. Yanni | 2003-11-11 |